Clinical review report: Burosumab (Crysvita) (Kyowa Kirin limited) indication: for the treatment of x-linked hypophosphatemia in adult and pediatric patients one year of age and older
The objective of this CADTH Common Drug Review is to perform a systematic review of the beneficial and harmful effects of burosumab for the treatment of X-linked hypophosphatemia in adult and pediatric patients one year of age and older
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
Canadian Agency for Drugs and Technologies in Health
2020, July 2020
|
| Edition: | Final |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this CADTH Common Drug Review is to perform a systematic review of the beneficial and harmful effects of burosumab for the treatment of X-linked hypophosphatemia in adult and pediatric patients one year of age and older |
|---|---|
| Physical Description: | 1 PDF file (197 pages) illustrations |